Sign Out
250 mg: If the patient is pregnant or breastfeeding, ask a doctor before use. It is especially important not to use mefenamic acid during the last three months of pregnancy unless definitely directed to do so by a doctor because it may cause problems in the unborn child or complications during delivery.
500 mg: Pregnancy: Pregnancy Category C. Mefenamic acid is contraindicated for use during the third trimester of pregnancy because of risk of premature closure or the ductus arteriosus and the potential to prolong labor and birth. It is not known if mefenamic acid or its metabolites crosses the placenta. Caution should be exercised in prescribing mefenamic acid during the first and second trimesters of pregnancy (see Contraindications).
Inhibition of prostaglandin synthesis may adversely affect pregnancy and/or the embryo-fetal development. Data from epidemiological studies suggest an increased risk of miscarriage and of cardiac malformation after use of a prostaglandin synthesis inhibitor in early pregnancy.
The use of mefenamic acid may impair female fertility and is not recommended in women attempting to conceive. In women who have difficulties conceiving or who are undergoing investigation of infertility, withdrawal of mefenamic acid should be considered.
Lactation: Trace amounts or mefenamic acid may be present in breast milk. Because of the potential for serious adverse reactions from mefenamic acid in breastfeeding infants, a decision should be made whether to discontinue breastfeeding or to discontinue the drug, taking into account the importance of the drug to the mother.
